{ { {FV: ₹10 Ticker: 500201 52-Week H/L: ₹619.90/326

Flash News Investment - - RECOMMENDATIONS -

We had rec­om­mended In­dia Glycols in Vol­ume no 34, Is­sue No 51 (dated Oct 08, 2018), when the scrip was trad­ing at Rs 417. Our rec­om­men­da­tion was backed by fac­tors like ro­bust fi­nan­cials and ris­ing de­mand across sec­tors. In Q2FY19, rev­enue rose by 7.03 per­cent YoY from Rs 888.26 crore to Rs 950.73 crore. EBITDA grew by 61.9 per­cent YoY from Rs 71 crore to Rs 115 crore and the EBITDA mar­gin stood at 12 per­cent as against 8 per­cent in Q2FY18. PAT for the quar­ter jumped by 197.2 per­cent YoY to Rs 43.6 crore from Rs 14.6 crore. PAT mar­gin stood at 4.6 per­cent in Q2FY19. The out- look for FY19 is pos­i­tive in terms of ro­bust growth in vol­umes and value. Thus, con­sid­er­ing the ro­bust per­for­mance, we urge in­vestors to HOLD the scrip.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.